Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes

Podobne zapisy

• Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes
  od: Xu, Feng, i wsp.
  Wydane: (2017)
• Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
  od: Li, Xiao, i wsp.
  Wydane: (2014)
• High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome
  od: Wu, Lingyun, i wsp.
  Wydane: (2016)
• Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes
  od: Xu, Feng, i wsp.
  Wydane: (2015)
• Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic Syndromes
  od: Li, Xiao, i wsp.
  Wydane: (2013)